A clear evidence-based rationale is provided to test calcitriol in combination with astemizole as an adjuvant in the management of VDR/Eag1-expressing breast cancer tumors, regardless of the presence of other molecular markers such as ER, PR or Her2-neu. Here, PGR is linked to breast carcinoma.